The Institute for Clinical and Economic Review recently evaluated rheumatoid arthritis drugs and awarded AbbVie’s Humira a “C” rating in their comparative effectiveness analysis. According to the report, Humira would need a net price discount of 50% to 69% to be cost-effective. Find out more here. (Source: Tracy Staton, FiercePharma, 4/10/17)
